Essential Evidence-Based Psychopharmacology (2nd Ed.)

Coordinators: Stein Dan, Lerer Bernard, Stahl Stephen M.

An evidence-based approach to psychopharmacology addressing the questions of optimal first line interventions, maintenance pharmacotherapy and management of treatment-refractory patients.

Language: English
Cover of the book Essential Evidence-Based Psychopharmacology

Subject for Essential Evidence-Based Psychopharmacology

Approximative price 78.50 €

In Print (Delivery period: 14 days).

Add to cartAdd to cart
Publication date:
334 p. · 15.7x23.4 cm · Paperback
This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
Preface; Foreword; 1. Evidence-based pharmacotherapy of attention deficit hyperactivity disorder Brigitte S. Vaughan, John S. March and Christopher J. Kratochvil; 2. Evidence-based pharmacotherapy of schizophrenia Stefan Leucht, Stephan Heres, Werner Kissling and John M. Davis; 3. Evidence-based pharmacotherapy of bipolar disorder Matthew J. Taylor and John R. Geddes; 4. Evidence-based pharmacotherapy of major depressive disorder Jamie M. Dupuy, Michael J. Ostacher, Jeffrey Huffman, Roy H. Perlis and Andrew A. Nierenberg; 5. Evidence-based pharmacotherapy of panic disorder Neeltje M. Batelaan, Anton J. L. M. Van Balkom and Dan J. Stein; 6. Evidence-based pharmacotherapy of social anxiety disorder Carlos Blanco, Laura B. Bragdon, Franklin R. Schneier and Michael R. Liebowitz; 7. Evidence-based pharmacotherapy of generalised anxiety disorder David S. Baldwin, Sarah Waldman and Christer Allgulander; 8. Evidence-based pharmacotherapy of obsessive-compulsive disorder Naomi A. Fineberg, Angus Brown and Ilenia Pampaloni; 9. Evidence-based pharmacotherapy of posttraumatic stress disorder Jonathan C. Ipser and Dan J. Stein; 10. Evidence-based pharmacotherapy of eating disorders Martine F. Flament, Hany Bissada and Wendy Spettigue; 11. Evidence-based pharmacotherapy of nicotine and alcohol dependence Wim van den Brink; 12. Evidence-based pharmacotherapy of illicit substance use disorders Wim van den Brink; 13. Evidence-based pharmacotherapy of Alzheimer's disease Darren Cotterell and Martin Brown; 14. Evidence-based pharmacotherapy of personality disorders Luis H. Ripoll, Joseph Triebwasser and Larry J. Siever; Index.
Dan J. Stein is Professor and Chair of the Department of Psychiatry at the University of Cape Town.
Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatric Laboratory at the Hadassah-Hebrew University Medical Center, Jerusalem.
Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of San Diego and Honorary Visiting Senior Fellow in Psychiatry at the University of Cambridge.